EventsMOL2NET'16, Conference on Molecular, Biomed., Comput. & Network Science and Engineering, 2nd ed.
Event submissions
Published
with-doi10.3390/mol2net-02-05038
This submission belongs to the session 03. USEDAT-02: USA-Europe Data Analysis Training Program Workshop, Cambridge, UK-Bilbao, Spain-Miami, USA, 2016 of the event MOL2NET'16, Conference on Molecular, Biomed., Comput. & Network Science and Engineering, 2nd ed.
Published date
25 Nov, 2017
Citation
Aliuska Duardo-Sanchez, CRISPR-Cas Gene Editing: Regulatory Issues and Applications, in Proceedings of MOL2NET'16, Conference on Molecular, Biomed., Comput. & Network Science and Engineering, 2nd ed., 15 October–20 October 2022, MDPI: Basel, Switzerland, doi: 10.3390/mol2net-02-05038
Share
Email
Facebook
Twitter
LinkedIn

CRISPR-Cas Gene Editing: Regulatory Issues and Applications

Aliuska Duardo-Sanchez 1
1. Department of Public Law, University of the Basque Country UPV/EHU, 48940, Leioa, Biscay, Spain
Abstract

CRISPR-Cas gene editing methods is an emerging powerful tools in biosciences. Applications of CRISPR to synthetics biology, biotechnology, personalized medicine, drug discovery etc, generates a series of legal and bioethics questions. This generates in turn the necessity of new regulatory issues. In this work we discuss more recent applications of CRIPSR focused on drug discovery with incidence of human genome information. This includes, but is not limited to: resistance-selection studies of antimalarial drugs; new animal models for drug assay, etc. We also, discuss the legal regulation and ethical aspects of this area of human genome editing related to drug discovery.

Keywords
CRISPR-Cas
Drug discovery
Human genome
Gene editing legal issues
Poster
mol2net-02_SRI08_2016_template.pdf
mol2net-02_SRI08_2016_template.pdf
Complex Network Analysis of General Tax Law
MOL2NET: FROM MOLECULES TO NETWORKS (PROC. BOOK) 2018, Vol. 2, 480 pp.